Cyclophosphamide

Generic Name
Cyclophosphamide
Brand Names
Procytox
Drug Type
Small Molecule
Chemical Formula
C7H15Cl2N2O2P
CAS Number
50-18-0
Unique Ingredient Identifier
6UXW23996M
Background

Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cance...

Indication

Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patien...

Associated Conditions
Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
Associated Therapies
-

A Multi-Institutional Phase II Study of Cyclophosphamide, Paclitaxel, Cisplatin With G-CSF for Patients With Newly Diagnosed Advanced Stage Ovarian Cancer

Phase 2
Completed
Conditions
First Posted Date
1999-11-04
Last Posted Date
2018-04-05
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
66
Registration Number
NCT00001426
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Diffuse Fibrotic Lung Disease

First Posted Date
1999-10-28
Last Posted Date
2013-11-26
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Registration Number
NCT00000596

Phase II Study of Bone Marrow Transplantation Using Related Donors in Patients With Aplastic Anemia

Phase 2
Completed
Conditions
First Posted Date
1999-10-19
Last Posted Date
2005-06-24
Lead Sponsor
National Center for Research Resources (NCRR)
Target Recruit Count
10
Registration Number
NCT00004323
Locations
🇺🇸

Center for Health Sciences, Los Angeles, California, United States

Phase III Randomized Study of Cyclophosphamide With or Without Antithymocyte Globulin Before Bone Marrow Transplantation in Patients With Aplastic Anemia

First Posted Date
1999-10-19
Last Posted Date
2018-03-12
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
224
Registration Number
NCT00004474
Locations
🇺🇸

Midwest Children's Cancer Center, Milwaukee, Wisconsin, United States

🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

🇺🇸

University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

and more 1 locations

Study of High Dose Cyclophosphamide in Patients With Severe Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria

First Posted Date
1999-10-19
Last Posted Date
2019-01-18
Lead Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Target Recruit Count
69
Registration Number
NCT00004464
Locations
🇺🇸

Johns Hopkins Oncology Center, Baltimore, Maryland, United States

© Copyright 2024. All Rights Reserved by MedPath